Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.
about
Reduced intestinal tumorigenesis in APCmin mice lacking melanin-concentrating hormone.Emerging treatment options for short bowel syndrome: potential role of teduglutideLosing balance: Hardy-Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancerIntestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in miceEnteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic TissuesThe therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.The "cryptic" mechanism of action of glucagon-like peptide-2.Review article: a comparison of glucagon-like peptides 1 and 2.Effect of porcine glucagon-like peptides-2 on tight junction in GLP-2R + IPEC-J2 cell through the PI3 k/Akt/mTOR/p70S6K signalling pathway.The Effects of Glucagon-like Peptide-2 on the Tight Junction and Barrier Function in IPEC-J2 Cells through Phosphatidylinositol 3-kinase-Protein Kinase B-Mammalian Target of Rapamycin Signaling PathwayGlucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.Glucagon like peptide-2 and neoplasia; a systematic review.Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.Increased GLP2R expression in gastric chief cells of patients with severe obesity regardless of diabetes status.
P2860
Q34359222-AB5DB5AF-7BC5-4610-9835-5427B4433FF0Q35304614-578B1F9A-960B-46C6-A223-4AFCF62C371AQ35565689-910FC2AE-D5EC-4F5D-A831-E76BC340CED0Q35986076-7FCC5D23-6AED-47FA-8E0E-942B3ABED6ECQ36309586-49CAB348-91C9-489E-B586-3BE284C0642AQ36665328-ED33580D-A81E-4840-AFDB-1852DD62856AQ37840099-1BD93609-7980-46D9-AD65-187DD992641CQ37870031-CAE4B525-C334-4AEF-89E6-6718E7A4EB9CQ38057350-BEF8C3E8-D6D3-4C91-B41C-2E04CC599B3CQ38718059-320101CE-E89E-439C-ADB8-86DB6EC44365Q40849359-7D4005C8-6337-4FED-A644-04847636CE9EQ42721362-79C6199F-2512-4A9E-B023-960F624C488DQ49901206-7DC154AE-AD71-4170-AC90-48EADA349DD7Q51015187-6F6B994D-DCAD-426B-974C-67DB5B17A80CQ53405267-69D0ECAB-1CCB-4500-84CD-9C62B3D80610
P2860
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Glucagon-like peptide-2 does n ...... human intestinal tumor cells.
@ast
Glucagon-like peptide-2 does n ...... human intestinal tumor cells.
@en
type
label
Glucagon-like peptide-2 does n ...... human intestinal tumor cells.
@ast
Glucagon-like peptide-2 does n ...... human intestinal tumor cells.
@en
prefLabel
Glucagon-like peptide-2 does n ...... human intestinal tumor cells.
@ast
Glucagon-like peptide-2 does n ...... human intestinal tumor cells.
@en
P2093
P2860
P1433
P1476
Glucagon-like peptide-2 does n ...... human intestinal tumor cells.
@en
P2093
Bernardo Yusta
Jacqueline A Koehler
Maja Barnard
Will Harper
P2860
P304
P356
10.1158/0008-5472.CAN-08-0029
P407
P577
2008-10-01T00:00:00Z